XML 90 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
License and Research Agreements - Solid Biosciences, Inc. - Additional Information (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 31, 2022
shares
Oct. 31, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Common stock investment value       $ 82 $ 70
Solid Biosciences, Inc.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Remaining consideration paid     $ 13,200    
Business acquisition, consideration transferred     $ 40,000    
Common stock investment value   $ 26,800      
Description of the stock split In October 2022, Solid announced a 1 for 15 reverse stock split. After the split, the Company held 521,719 shares of Solid's common stock.        
stock split conversion ratio 1        
Number of common shares held after split | shares 521,719        
Collaboration Agreement | Solid Biosciences, Inc.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of common stock purchased | shares   7,825,797      
Aggregate purchase price   $ 40,000      
Maximum | Collaboration and License Agreement | Solid Biosciences, Inc.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development milestone payments   25,000      
Regulatory milestone payments   65,000      
Commercial milestone payments   $ 165,000